企業プロフィール
Lucid Diagnostics 株価・ニュース・カタリスト
- ティッカー:
- LUCD
- 取引所:
- NASDAQ
- セクター:
- MedTech
- 所在地:
- United States
株価パフォーマンス
0.96 USD (+0.41%)
終値
最終更新: 2026年8月21日
196M USD
時価総額
株価変動の要因
As of Aug 21, 2026, LUCD closed up 0.41% at $0.9643. No new same-company headline was identified in the current news window.
企業概要
Esophageal Cancer Prevention Company
Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease.
EsoGuard and EsoCheck
The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection device. Together, the products are designed to identify at-risk patients before esophageal cancer develops.
Commercial and Reimbursement Model
Lucid generates revenue from processed EsoGuard tests while building adoption through gastroenterologists, health systems, commercial payers, Medicare, and the Veterans Health Administration.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。